Articles By Wayne Koberstein
-
Style & Substance In The Pharma Supplier Space
11/27/2013
What is real, and what is illusory in the world of drug, diagnostic, and device development?
-
A Bullish Season At The Time BIO Investors Forum
11/27/2013
The BIO Investor Forum had a unique mood with a shift in content from previous years with less focus on the downside of VC funding and IPO action and more focus on partnering, noncancer conditions, and new cancer treatment modes.
-
Companies To Watch: Vivaldi Biosciences
11/1/2013
Vivaldi biosciences is aiming to parlay its new vaccine target a live-cell approach to accomplish an unprecedented level of protection against the flu, using live attenuated influenza vaccines (LAIVs) to stimulate multiple arms of the immune systems: antibodies, T-cells, and interferon.
-
Companies To Watch: Inovio
10/2/2013
Inovio is developing DNA-based vaccines and its Cellectra Electroporation Delivery Technology platform are providing positive results from animal studies for HIV, malaria, tumors and influenza.
-
AstraZeneca Translates 'Winning With Science' From Words To Action
8/29/2013
An exclusive interview with Menelas Pangalos, executive VP of innovative medicines at AstraZeneca, one of the three direct-to-CEO reports, responsible for small-molecule discovery and early-stage (through Phase 2) development.
-
Esperion Therapeutics, Does Their Cholesterol-Reduction Drug Have “Blockbuster Potential”?
8/29/2013
Esperion CEO, Tim Mayleben says “Success for Esperion will be if ETC-1002 completes clinical development, is approved, and is prescribed by physicians for the millions of patients who can’t tolerate statins or can’t get to their LDL-C goal”. As one of the relative few mid-stage developers of new drugs with blockbuster potential, Esperion could be headed for membership of that elite club.
-
Companies To Watch: Soligenix
7/1/2013
Strong federal support and a unique model centered on biodefense therapeutics and vaccines drive this company — and our interest in it.
-
Companies To Watch: Cempra
6/3/2013
Cempra is one of a rare but expanding breed of companies answering the call for new antibiotics.
-
Companies To Watch: Immune Pharmaceuticals
5/1/2013
Immune Pharmaceuticals is a renewed and broader company as the result of its merger with EpiCept.
-
Companies To Watch: StemCells
4/1/2013
StemCells has a cautious agenda in developing tissue-derived adult stem cell therapeutics that could lead to big leaps in patients’ quality of life.